Professor Borislava Mihaylova

Contact information

Telephone
+44 (0)1865 289226

Borislava Mihaylova

MSc, DPhil

Professor of Health Economics

Health Economics Research Centre

Borislava (Boby) Mihaylova is Professor of Health Economics at the Health Economics Research Centre in Oxford Population Health.

Her research programme focuses on economic aspects of chronic disease (such as cardiovascular, chronic kidney disease and diabetes) and comprises studies of the impact of disease events and interventions on morbidity, mortality, health-related quality of life and healthcare costs; development of disease models to evaluate long-term effects of disease and interventions, cost-effectiveness analyses of healthcare interventions and studies of socio-economic determinants of health.

She is leading/has led the development of the economic analyses in a number of large randomised controlled trials (EMPA-KIDNEY, ACST-2, REVEAL, SHARP, THRIVE) and in the individual participant data meta-analysis of statin trials (Cholesterol Treatment Collaboration).

Her work on effectiveness and cost-effectiveness of statins for cardiovascular disease prevention in the Heart Protection Study and the Cholesterol Treatment Collaboration has been influential in informing treatment recommendations for people at different vascular disease risk.

Key publications

Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial.

Thomson DJ. et al, (2026), Lancet

Liquid biopsy for the diagnosis of EBV-positive Burkitt's lymphoma in endemic areas.

Chamba C. et al, (2026), Nat Med

Lifetime Effects of Adherence to Cardiovascular and Diabetes Medications in Spain: A Modelling Study in a Population Cohort of 152,117 Patients.

Sánchez-Viñas A. et al, (2026), Pharmacoeconomics

A Decision-Support System to Personalize Antidepressant Treatment in Major Depressive Disorder: A Randomized Clinical Trial.

Cipriani A. et al, (2026), JAMA

Economic Evaluations of Medication Safety Interventions in Primary and Long-Term Care: A Systematic Review.

Amritlal ST. et al, (2026), Pharmacoeconomics, 44, 299 - 316

Optimising the monitoring and management of raised blood pressure including proteinuria testing during pregnancy: the BUMP research programme including 2 RCTs

McManus RJ. et al, (2026), Programme Grants for Applied Research, 1 - 50

Economic evaluations in the palliative and end-of-life care settings: A systematic review of existing evidence, methods and quality.

Fischer C. et al, (2026), Palliat Med

Towards a Multi-sectoral Approach to Population Health: A Scoping Review of Cross-sectoral Evaluations of Health Interventions.

Koleva-Kolarova R. et al, (2026), Appl Health Econ Health Policy

Follow-up of suspected child maltreatment cases treated at a tertiary child protection service facility.

Mora-Theuer EA. et al, (2026), Eur J Pediatr, 185

Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania.

Jiang J. et al, (2026), BMC Med

Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.

Pearson C. et al, (2026), Lancet Oncol

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials

REITH C. et al, (2026), The Lancet

Substantial variation in the cost of blood group and save and crossmatch: a systematic review

Fabiano G. et al, (2026), British Journal of Haematology

Improving Collaborative Engagement in Health State Valuation: A Scoping Review of Current Practices and Emerging Recommendations.

Powell PA. et al, (2026), Pharmacoeconomics, 44, 141 - 163

Theoretically Universal, Practically Unequal: Socio-Economic Inequalities in Healthcare Access for Long Covid-19 Patients in Austria.

Gamillscheg-Müllner P. et al, (2026), Health Expect, 29

Gabapentin as an adjunct to multimodal pain regimens in surgical patients: the GAP placebo-controlled RCT and economic evaluation.

Baos S. et al, (2026), Health Technol Assess, 30, 1 - 144

Cost-effectiveness of pramipexole augmentation for acute phase and maintenance therapy of treatment-resistant depression compared to placebo augmentation: economic evaluation of the PAX-D randomised controlled trial.

Łaszewska A. et al, (2026), Lancet Reg Health Eur, 61

Improving outcomes in adult patients who self-harm-evaluating a brief psychological intervention in emergency departments (ASSURED): protocol of a randomised controlled clinical trial.

McCabe R. et al, (2026), Trials

Estimating the Potential Impact of the 2024 UK Salt Reduction Targets on Cardiovascular Health Outcomes and Health Care Costs in Adults: A Modeling Study

Bandy L., (2026), Hypertension

Corrigendum to "Accuracy of online surveys in predicting COVID-19 vaccine uptake and demand: A cohort study investigating vaccine sentiments and switching in 13 countries from 2020 to 2022" [Vaccines 62 (2025) 127450].

Abel ZDV. et al, (2026), Vaccine, 71

EQ-5D vision bolt-on in macular degeneration: Associations with visual measures and effect on utility differences and cost-effectiveness of stereotactic radiotherapy

Zhu X. et al, (2026), Health and Quality of Life Outcomes

Translation, cross-cultural adaptation, and validation of the Caregiver Indirect and Informal Care Cost Assessment Questionnaire for end-of-life care into Spanish.

Lamfre LS. et al, (2026), Palliat Support Care, 24

Avoiding routine gastric residual volume measurement in neonatal critical care (the neoGASTRIC trial): study protocol for a multi-centre, unblinded, randomised, controlled trial

NUTHALL E. et al, (2026), Trials

Parent-led CBT delivered via online and telephone support alongside usual school practice versus usual school practice only for young children identified as at-risk for anxiety disorders through screening in schools: a cluster randomised controlled trial

REARDON T., (2026), Journal of Child Psychology and Psychiatry

Association between health literacy and reproductive health knowledge and behavior : A cross-sectional survey among women of reproductive age in Vienna.

Rottjakob P. et al, (2026), Wien Klin Wochenschr

Correction: Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England.

Buckell J. et al, (2026), Br J Cancer, 134, 175 - 176

Roux-en-Y gastric bypass, adjustable gastric banding or sleeve gastrectomy for severe obesity: The By-Band-Sleeve randomised controlled trial.

(2026), Health Technol Assess, 30, 1 - 224

Correspondence on "Parents' perceptions of the utility of genetic testing in the NICU" by Callahan et al.

Sansom SL. et al, (2026), Genet Med, 28

Comparing Adolescent and Adult Preferences for EQ-5D-Y-3L Health States in Hong Kong.

Wang K. et al, (2026), Value Health, 29, 139 - 148

Factors associated with hospitalisations, emergency visits and related costs in inflammatory bowel disease: insights from the TrueColours-IBD digital monitoring programme in Oxford

Fierens L. et al, (2026), JOURNAL OF CROHNS & COLITIS, 20

Trial protocol: DOLFIN trial: Developmental Outcomes of Long-term Feed Supplementation in Neonates-A UK multicentre, blinded, stratified, randomised controlled trial.

Andrew MJ. et al, (2025), Trials, 26

Economic effects for citizens and the government of a country-level tobacco endgame strategy: a modelling study.

Ait Ouakrim D. et al, (2025), Tob Control, 34, e9 - e16

The HERC Database of Mapping Studies: a 2025 update of a live systematic review of studies predicting EQ-5D from other patient-reported outcome measures

Mallon K. et al, (2025), Value in Health, 28, s534 - s535

Patient-reported harm from NHS treatment or care, or the lack of access to care: a cross-sectional survey of general population prevalence, impact and responses.

Crocker H. et al, (2025), BMJ Qual Saf, 35, 30 - 42

Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial.

Berger M. et al, (2025), J Affect Disord, 391

Cost Effectiveness of Local Anaesthetic Transperineal Versus Transrectal Biopsy: Results from the TRANSLATE Study.

Little M. et al, (2025), Eur Urol Focus

Mapping the benefits and harms of antenatal and newborn screening programmes

HINTON L. et al, (2025), SSM: Qualitative Research in Health

Prevalence of cognitive morbidity including delirium in 51,202 emergency hospital admissions across 29 medical and surgical specialties in ORCHARD-EPR: a cross-sectional study.

Boucher EL. et al, (2025), EClinicalMedicine, 90

Proactive Integrated Consultation-Liaison Psychiatry for older medical inpatients: The HOME Study RCT of its effectiveness and cost-effectiveness.

Sharpe M. et al, (2025), Health Soc Care Deliv Res, 13, 1 - 85

Quality of life of primary caregivers by severity and control of children's asthma: a systematic review and meta-analysis.

Tomini F. et al, (2025), Qual Life Res, 34, 3425 - 3445

Barriers, facilitators, and the role of central coordination: understanding long COVID-19 healthcare access in a universal healthcare system.

Gamillscheg-Müllner P. et al, (2025), Arch Public Health, 83

Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET): study protocol for a pragmatic Randomised Control Trial of a patient-centred intervention to improve adherence to endocrine therapy in early breast cancer

Mcgeagh L. et al, (2025), Trials

2025 ESC/EACTS Guidelines for the management of valvular heart disease.

Praz F. et al, (2025), Eur Heart J, 46, 4635 - 4736

2025 ESC Guidelines for the management of cardiovascular disease and pregnancy.

De Backer J. et al, (2025), Eur Heart J, 46, 4462 - 4568

SurfON Trial: Study Protocol for a multicentre, open-label, randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress.

Boyle EM. et al, (2025), Trials

Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study.

Jamieson T. et al, (2025), Eur J Health Econ

Optimising antibiotic “review and revise” in acute/general medical inpatients: the Antibiotic Review Kit in Hospitals (ARK-Hospital) research programme including a stepped-wedge cluster-randomised trial

Llewelyn MJ. et al, (2025), NIHR Journals Library

Validation and cost-effectiveness of an mHealth tool for cognitive impairment detection in Peru: protocol for the IMPACT Salud observational study.

Cardenas MK. et al, (2025), BMJ Open, 15

HERC database of mapping studies, Version 10.0

DAKIN H. et al, (2025)

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.

Mach F. et al, (2025), Eur Heart J, 46, 4359 - 4378

2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease: developed under the auspices of the ESC Clinical Practice Guidelines Committee.

Bueno H. et al, (2025), Eur Heart J, 46, 4156 - 4225

Cost-effectiveness of CA125- and age-informed risk-based triage for ovarian cancer detection in primary care.

Wu R. et al, (2025), Br J Cancer, 133, 1492 - 1500

Recent publications